Search Prime Contracts

75N93020C00018

Definitive Contract

Overview

Government Description
TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.
Awardee
Revagenix
Awarding / Funding Agency
National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
AN12 - Health R&D Services; Health Care Services; Applied Research
Place of Performance
San Diego, CA 92101 United States
Pricing
Cost Plus Fixed Fee
Set Aside
None
Extent Competed
Full And Open Competition
Related Opportunity
2019 NIAID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2019-1)
Analysis Notes
Amendment Since initial award the Potential End Date has been extended from 06/30/21 to 08/31/26 and the Potential Award value has increased 56% from $20,401,780 to $31,725,939.
Undisclosed Subcontractors No subcontract awards have been formally disclosed for this contract; however, based on invoice data these subcontractors have worked on this contract: Dipharma, X-Chem
Revagenix was awarded Definitive Contract 75N93020C00018 (75N930-20-C-00018) worth up to $31,725,939 by the National Institute of Allergy and Infectious Diseases in July 2020. The contract has a duration of 6 years 1 months and was awarded through solicitation 2019 NIAID Omnibus Broad Agency Announcement full & open with NAICS 541715 and PSC AN12 via direct negotiation acquisition procedures with 12 bids received. As of today, the Definitive Contract has a total reported backlog of $6,915,350.

Status
(Open)

Last Modified 4/29/25
Period of Performance
7/1/20
Start Date
8/31/26
Current End Date
8/31/26
Potential End Date
80.0% Complete

Obligations and Backlog
$24.8M
Total Obligated
$24.8M
Current Award
$31.7M
Potential Award
78% Funded
$0.0
Funded Backlog
$6.9M
Total Backlog

Award Hierarchy

Definitive Contract

75N93020C00018

Subcontracts

0

Activity Timeline

Interactive chart of timeline of amendments to 75N93020C00018

Labor Services Billing

Annual labor billing rates and FTE reported for 75N93020C00018

Year Services Invoiced Hours FTE Blended Rate
2020 $295,984 843.5 0.4 $350.90
2021 $2,959,702 6,465.0 3.1 $457.80
2023 $4,200,885 12,079.6 5.8 $347.77

Opportunity Lifecycle

Procurement history for 75N93020C00018

Transaction History

Modifications to 75N93020C00018

People

Suggested agency contacts for 75N93020C00018

Competition

Number of Bidders
12
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No

Other Categorizations

Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
D98QFZUPFXJ9
Awardee CAGE
8B1Y9
Agency Detail
Awarding Office
75N930 NATIONAL INSTITUTES OF HEALTH NIAID
Funding Office
75N930
Created By
hhsteosl
Last Modified By
hhsteosl
Approved By
hhsteosl

Legislative

Legislative Mandates
None Applicable
Performance District
CA-50
Senators
Dianne Feinstein
Alejandro Padilla
Representative
Scott Peters

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) Health research and training Research and development contracts (25.5) $14,765,999 100%
Modified: 4/29/25